Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The pacemakers, insulin pumps, and neurostimulators that power Medtronic’s reputation live inside millions of patients—and inside hundreds of dense SEC documents. Product recalls, FDA approvals, and global tax disclosures can stretch a single Medtronic annual report beyond 300 pages, leaving many investors asking ‘where do I find the real story?’
StockTitan answers that question the moment a document hits EDGAR. Our platform ingests every Medtronic 10-K, 10-Q, 8-K, and Form 4, then deploys AI-powered summaries so Medtronic SEC filings explained simply is more than a promise. Need Medtronic insider trading Form 4 transactions or a heads-up on director buys? Real-time alerts flag Medtronic Form 4 insider transactions real-time as they occur. Prefer big-picture context? AI pulls segment revenue and margin shifts straight from the latest Medtronic quarterly earnings report 10-Q filing and packages them into concise dashboards.
Dig deeper with one click: targeted tags guide you to R&D spend, international tax notes, and safety disclosures inside the Medtronic annual report 10-K simplified. Governance questions? The Medtronic proxy statement executive compensation view highlights pay-for-performance metrics, while Medtronic 8-K material events explained keeps you ahead of recalls or FDA warnings. Whether you’re comparing cash-flow trends, tracking Medtronic executive stock transactions Form 4, or seeking a fast Medtronic earnings report filing analysis, our AI delivers the clarity you need for confident decisions—understanding Medtronic SEC documents with AI has never been easier.
Michael Marinaro, Executive Vice President, President MedSurg and Americas at Medtronic plc (MDT), reported a disposition of 1,052 ordinary shares on 08/20/2025. The shares were disposed at a reported price of $93.22 and the filing states this transaction represents shares withheld for payment of taxes upon vesting of previously reported restricted stock units. After the transaction, Marinaro beneficially owned 51,939 ordinary shares. The Form 4 is signed by an attorney-in-fact, Patricia Walesiewicz, dated 08/21/2025. The filing discloses only the withholding tax disposition and current beneficial ownership.
Medtronic director filing reports no beneficial ownership. The Form 3 shows William R. Jellison as a director of Medtronic plc (MDT) and indicates he does not beneficially own any ordinary shares or derivative securities. The filing was submitted as an initial statement and was signed by an attorney-in-fact. No transactions, holdings, or indirect ownership interests are reported.
John P. Groetelaars filed an initial Form 3 reporting his relationship to Medtronic plc (MDT) as a Director and stating that he does not beneficially own any ordinary shares as of the event date 08/19/2025. The filing indicates it was submitted by one reporting person and was signed on behalf of Groetelaars by an attorney-in-fact, Patricia Walesiewicz. The form fulfills Section 16(a) reporting requirements for an insider initial ownership statement and contains an explicit declaration that no securities are beneficially owned.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
